Integrative role of neuropeptides and cytokines in cancer anorexia-cachexia syndrome

Clinica Chimica Acta

Volumn 413, Issue 13-14, 2012, Pages 1025-1034

  Patra, Surajeet K ^a   Arora, Sarika ^b  

^a LADY HARDINGE MEDICAL COLLEGE   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Anorexia; Cachexia; Cytokines; Leptin; Neuropeptide y; Neuropeptides

Indexed keywords

AGOUTI RELATED PROTEIN; ALPHA INTERMEDIN; CHOLECYSTOKININ; CILIARY NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GALANIN; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; LEUKEMIA INHIBITORY FACTOR; MELANIN CONCENTRATING HORMONE; MELANOCORTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; OPIATE PEPTIDE; OREXIN; PROOPIOMELANOCORTIN; TUMOR NECROSIS FACTOR ALPHA; UROCORTIN;

ANOREXIA; ARCUATE NUCLEUS; CACHEXIA; CACHEXIA ANOREXIA SYNDROME; CALORIC INTAKE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENERGY BALANCE; FOOD INTAKE; HUMAN; HYPERGLUCAGONEMIA; HYPOTHALAMIC PARAVENTRICULAR NUCLEUS; LIPOLYSIS; NEOPLASM; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; THERMOGENESIS; TUMOR GROWTH; TUMOR VOLUME; WASTING SYNDROME; WEIGHT REDUCTION;

ANOREXIA; CACHEXIA; CYTOKINES; HUMANS; NEOPLASMS; NEUROPEPTIDES; SYNDROME;

AGOUTI;

EID: 84860379595     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.12.008     Document Type: Review

References (179)

1. Gordon J.N., Green S.R., Goggin P.M. Cancer cachexia. QJM 2005, 98:779-788.
2. Dhanapal R., Saraswathi T.R., Rajkumar N.G. Cancer cachexia. J Oral Maxillofac Pathol 2011, 15:257-260.
3. Tisdale M. Molecular pathways leading to cancer cachexia. Physiology 2005, 20:340-348.
4. Bruera E. Anorexia, cachexia and nutrition. Br Med J 1997, 315:1219-1222.
5. Larkin M. Thwarting the dwindling progression of cachexia. Lancet 1998, 351:1336.
6. Plata-Salaman C.R. Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991, 15:185-215.
7. Plata-Salaman C.R. Anorexia during acute and chronic disease. Nutrition 1996, 12:67-78.
8. Schwartz M.W., Dallman M.F., Woods S.C. Hypothalamic response to starvation: implications for study of wasting disorders. Am J Physiol 1995, 269:R949-R957.
9. Hirai K., Hussey H.J., Barber M.D., Price S.A., Tisdale M.J. Biological evaluation of a lipid-mobilizing factor isolated from the urine of cancer patients. Cancer Res 1998, 58:2359-2365.
10. Rubin H. Cancer cachexia, its correlations and causes. Med Sci 2003, 100:5384-5389.
11. Noguchi Y., Yoshikawa T., Matsumoto A., Svaninger G., Gelin J. Are cytokines possible mediators of cancer cachexia?. Surg Today 1996, 26:467-475.
12. Matthys P., Billiau A. Cytokines and cachexia. Nutrition 1997, 13:763-770.
13. Gelin J., Moldawer L.L., Lonnroth C. Role of endogenous tumor necrosis factor α and interleukin-1 for experimental tumor growth and the development of cancer cachexia. Cancer Res 1991, 51:415-421.
14. Ryden M., Arvidsson E., Blomqvist L., Perbeck L., Dicker A., Arner P. Targets for TNFα-induced lipolysis in human adipocytes. Biochem Biophys Res Commun 2004, 318:168-175.
15. Price S.R., Olivecrona T., Pekala P.H. Regulation of lipoprotein lipase synthesis by recombinant tumor necrosis factor: the primary regulatory role of the hormone in 3T3-L1 adipocytes. Arch Biochem Biophys 1986, 251:738-742.
16. Berg M., Fraker D.L., Alexander H.R. Characterization of differentiation factor/leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994, 6:425-432.
17. Thompson M.P., Cooper S.T., Parry B.R., Tuckey J.A. Increased expression of the mRNA for hormone-sensitive lipase in adipose tissue of cancer patients. Biochim Biophys Acta 1993, 1180:236-242.
18. Zhang H.H., Halbleib M., Ahmad F., Manganiello V.C., Greenberg A.S. Tumor necrosis factor-α stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP. Diabetes 2002, 51:2929-2935.
19. Souza S., Moitoso de Vargas L., Yamamoto M., et al. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor to increase adipocyte lipolysis in 3T3-L1 adipocytes. J Biol Chem 1998, 273:24665-24669.
20. Laurencikiene J., van Harmelen V., Norelström E.A., et al. NF-κB is important for TNF-α-induced lipolysis in human adipocytes. J Lipid Res 2007, 48:1069-1077.
21. Busquets S., Sanchis D., Alvarez B., Ricquier D., Lopez-Soriano F.J., Argiles J.M. In the rat, tumor necrosis factor α administration results in an increase in both UCP2 and UCP3 mRNA in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis?. FEBS Lett 1998, 440:348-350.
22. Karayiannakis A.J., Syrigos K.N., Polychronidis A., Pitakoudis M., Bounovas A., Simppoulos K. Serum levels of tumor necrosis factor-α and nutritional status in pancreatic cancer patients. Anticancer Res 2001, 21:1355-1358.
23. Mader S., Lee H., Pause A., Sonenberg N. The translation initiation factor eIF-4E binds to a common motif shared by the translation factor eIF-4E gamma and the translational repressors 4E-binding proteins. Mol Cell Biol 1995, 15:4990-4997.
24. Barber M.D., Fearon K.C.H., Ross J.A. Relationship of serum levels of interleukin-6, soluble interleukin-6 receptor and tumor necrosis factor receptors to the acute-phase protein response in advanced pancreatic cancer. Clin Sci 1999, 96:83-87.
25. Strassman G., Fong M., Kenney J.S., Jacob C.O. Evidence for the involvement of interleukin 6 in experimental cancer cachexia. J Clin Invest 1992, 89:1681-1684.
26. Soda K., Kawakami M., Kashii K., Miyata M. Manifestation of cancer cachexia induced by colon 26 adenocarcinoma are not fully ascribable to interleukin-6. Int J Cancer 1995, 62:332-336.
27. Maltoni M., Fabbri L., Nanni O., et al. Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients. Support Care Cancer 1997, 5:130-135.
28. Martin F., Santolaria F., Batista N., et al. Cytokine levels (IL-6 and IFNγ), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999, 11:80-86.
29. Iwase S., Murakami T., Sato Y., Nakagawa K. Steep elevation of blood interleukin-6 (IL-6) associated only with the late stages of cachexia in cancer patients. Eur Cytokine Netw 2004, 15:312-316.
30. Henderson J.T., Mullen B.J.M., Roder J.C. Physiological effects of CNTF-induced wasting. Cytokine 1996, 8:784-793.
31. Moldawer L.L., Andersson C., Gelin J., Lundholm K.G. Regulation of food intake and hepatic protein synthesis by recombinant-derived cytokines. Am J Physiol Gastrointest Liver Physiol 1988, 254:G450-G456.
32. Espat N.J., Auffenberg T., Rosenberg J.J., et al. Ciliary neutrophic factor is catabolic and shares with IL-6 the capacity to induce an acute phase response. Am J Physiol Regul Integr Comp Physiol 1996, 271:R185-R190.
33. Agustsson T., Ryden M., Hoffstedt J., et al. Mechanism of increased lipolysis in cancer cachexia. Cancer Res 2007, 67:5531-5537.
34. Moldawer L.L., Copeland E.M. Proinflammatory cytokines, nutritional support and the cachexia syndrome. Cancer (Phila.) 1997, 79:1828-1839.
35. Sternberg E.M. Neural-immune interactions in health and disease. J Clin Invest 1997, 100:2641-2647.
36. Licinio J., Wong M.-L. Pathways and mechanisms for cytokine signaling of the central nervous system. J Clin Invest 1997, 100:2941-2947.
37. Hopkins S.J., Rothwell N.J. Cytokines and the nervous system: expression and recognition. Trends Neurosci 1995, 18:83-88.
38. Rothwell N.J., Hopkins S.J. Cytokines and the nervous system: actions and mechanisms of action. Trends Neurosci 1995, 18:130-136.
39. Sherry B.A., Gelin J., Fong Y. Anticachectin/tumor necrosis factor-α antibodies attenuate development of cachexia in tumor models. FASEB J 1989, 3:1956-1962.
40. Haslett P.A.J. Anticytokine approaches to the treatment of anorexia and cachexia. Semin Oncol 1998, 25(Suppl. 6):53-57.
41. Mantovani G., Maccio A., Lai P., Massa E., Ghiani M., Santona M.C. Cytokine activity in cancer-related anorexia/cachexia: role of megastrol acetate and medroxyprogesterone acetate. Semin Oncol 1998, 25(Suppl. 6):45-52.
42. Goehler L.E., Busch C.R., Tartaglia N., et al. Blockade of cytokine induced conditioned taste aversion by subdiaphragmatic vagotomy: further evidence for vagal mediation of immune-brain communication. Neurosci Lett 1995, 185:163-166.
43. Lira F.S., Yamashita A.S., Rosa J.C., Tavares F.L., Caperuto E., Carnevali L.C., et al. Hypothalamic inflammation is reversed by endurance training in anorectic cachectic rats. Nutr Metab 2011, 8:60.
44. Morley J.E., Farr S.A. Cachexia and neuropeptide Y. Nutrition 2008, 24:815-819.
45. Flier J.S., Maratos-Flier E. Obesity and the hypothalamus: novel peptides for new pathways. Cell 1998, 92:437-440.
46. Wood S.C., Seeley R.J., Porte D., Schwartz M.W. Signals that regulate food intake and energy homeostasis. Science 1998, 280:1378-1383.
47. Friedman J.M., Halaas J.L. Leptin and the regulation of body weight in mammals. Nature 1998, 395:763-770.
48. Inui A. Feeding and body weight regulation by hypothalamic neuropeptides - mediation of the actions of leptin. Trends Neurosci 1999, 22:62-67.
49. Perboni S., Inui A. Anorexia in cancer: role of feeding-regulatory peptides. Philos Trans R Soc B 2006, 361:1281-1289.
50. Collins S., Kuhn C.M., Petro A.E., Swick A.G., Chrunyk B.A., Surwit R.S. Role of leptin in fat regulation. Nature 1996, 380:677.
51. Fleury C., Neverova M., Collins S., et al. Uncoupling protein 2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet 1997, 15:269-272.
52. Gong D.W., He Y., Karas M., Reitman M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, ß3-adrenergic agonists, and leptin. J Biol Chem 1997, 272:24129-24132.
53. Bray G.A., York D.A. The MONA LISA hypothesis in the time of leptin. Recent Prog Horm Res 1998, 53:95-1188.
54. Zhang Y., Proenca R., Maffei M., Barone M., Leopold L., Friedman J.M. Positional cloning of the mouse ob gene and its human homologue. Nature 1994, 372:425-432.
55. Trayhurn P., Hoggard N., Mercer J.G., Rayner D.V. Leptin: fundamental aspects. Int J Obes Relat Metab Disord 1999, 23(1):22-28.
56. Trayhurn P., Hoggard N., Rayner D.V. White adipose tissue as a secretory and endocrine organ: leptin and other secreted proteins. Adipose Tissue 2001, Landes Bioscience, Austin, TX. S. Klaus (Ed.).
57. Masuzaki H., Ogawa Y., Hosoda K., et al. Glucocorticoid regulation of leptin synthesis and secretion in humans: elevated plasma leptin levels in Cushing's Syndrome. JCEM 1997, 82:2542-2547.
58. Flier J.S. What's in a name? In search of leptin's physiological role. J Clin Endocrinol Metab 1998, 83:1407-1413.
59. Schwartz M.W., Figlewicz D.P., Baskin D.G., Woods S.C., Porte D. Insulin in the brain: a hormonal regulator of energy balance. Endocr Rev 1992, 13:387-414.
60. Arora S., Anubhuti Role of neuropeptides in appetite regulation and obesity - a review. Neuropeptide 2006, 40:375-401.
61. Zhang F.M., Basinski M.B., Beals J.M. Crystal structure of the obese protein leptin-E100. Nature 1997, 387:206-209.
62. Plata-Salaman C.R. Anorexia induced by activators of the signal transducer gp130. Neuroreport 1996, 7:841-844.
63. Sarraf P., Frederich R.C., Turner E.M., et al. Multiple cytokines and acute inflammation raise mouse leptin levels: potential role in inflammatory anorexia. J Exp Med 1997, 185:171-175.
64. Grunfeld C., Zhao C., Fuller J., et al. Endotoxin and cytokines induce expression of leptin, the ob gene product, in hamsters. J Clin Investig 1996, 97:2152-2157.
65. Finck B.N., Kelley K.W., Dantzer R., Johnson R.W. In vivo and in vitro evidence for the involvement of tumor necrosis factor-α in the induction of leptin by lipopolysaccharide. Endocrinology 1998, 139:2278-2283.
66. Bessesen D.H., Faggioni R. Recently identified peptides involved in the regulation of body weight. Semin Oncol 1998, 25(Suppl. 6):28-32.
67. Faggioni R., Fuller J., Moser A., Feingold K.R., Grunfeld C. LPS-induced anorexia in leptin-deficient (ob/ob) and leptin receptor-deficient (db/db) mice. Am J Physiol 1997, 273:R181-R186.
68. Chance W.T., Sheriff S., Moore J., Peng F., Balasubramaniam A. Reciprocal changes in hypothalamic receptor binding and circulating leptin in anorectic tumor-bearing rats. Brain Res 1998, 803:27-33.
69. Jensen P.B., Blume N., Mikkelsen J.D., et al. Transplantable rat glucagonomas cause acute onset of severe anorexia and adipsia despite highly elevated NPY mRNA levels in the hypothalamic arcuate nucleus. J Clin Invest 1998, 101:503-510.
70. Simons J.P., Schols A.M., Campfield L.A., Wouters E.F., Saris W.H. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci Colch 1997, 93:273-277.
71. Wallace A.M., Satter N., McMillan D.C. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res 1998, 4:2977-2979.
72. Gloaguen I., Costa P., Demartis A., et al. Ciliary neurotrophic factor corrects obesity and diabetes associated with leptin deficiency and resistance. Proc Natl Acad Sci U S A 1997, 94:6456-6461.
73. Xu B., Dube M.G., Kalra P.S., et al. Anorectic effects of the cytokine, ciliary neurotrophic factor, are mediated by hypothalamic neuropeptide Y: comparison with leptin. Endocrinology 1998, 139:466-473.
74. Ghilardi N., Ziegler S., Wiestner A., Stoffel R., Heim M.H., Skoda R.C. Defective STAT signaling by the leptin receptor in diabetic mice. Proc Natl Acad Sci U S A 1996, 93:6231-6235.
75. Vaisse C., Halaas J.L., Horvath C.M., Darnell J.E., Stoffel M., Friedman J.M. Leptin activation of stat 3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat Genet 1996, 13:95-98.
76. Kalra S.P. Appetite and body weight regulation: is it all in the brain?. Neuron 1997, 19:227-230.
77. Inui A., Neuropeptide Y. Feeding receptors - are multiple subtypes involved?. Trends Pharmacol Sci 1999, 20:43-46.
78. Tatemoto K. Neuropeptide Y: complete amino acid sequence of the brain peptide. Proc Natl Acad Sci U S A 1982, 79:5485-54892.
79. Billington C.J., Briggs J.E., Harker S., Grace M., Levine A.S. Neuropeptide Y in hypothalamic paraventricular nucleus: a center coordinating energy balance. Am J Physiol 1994, 266:R1765-R1770.
80. King P.J., Williams G. Role of ARC NPY neurons in energy homeostasis. Drugs News Perspect 1998, 11:402-410.
81. Sahu A., Kalra S.P. Neuropeptidergic regulation of feeding behavior, neuropeptide Y. Trends Endocrinol Metab 1993, 4:217-224.
82. Qu D., Ludwig D.S., Gammeltoft S., et al. A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature 1996, 380:243-247.
83. Sakurai T., Amemiya A., Ishii M., et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 1998, 92:573-85.
84. Stanley B.G., Kyrkouli S.E., Lampert S., Leibowitz S.F. Neuropeptide Y chronically injected into the hypothalamus: a powerful neurochemical inducer of hyperphagia and obesity. Peptides 1986, 7:1189-1192.
85. Stanley B.G. Neuropeptide Y in multiple hypothalamic sites controls eating behavior, endocrine, and autonomic systems for body energy balance. The Biology of Neuropeptide Y and Related Peptides 1993, 457-509. Humana Press, Inc, Totowas. W.F. Colmers, C. Wahlestedt (Eds.).
86. Egawa M., Yoshimatsu H., Bray G. Neuropeptide Y suppresses sympathetic activity to interscapular brown adipose tissue in rats. Am J Physiol 1991, 260:R328-R334.
87. Zarjevski N., Cusin I., Vettor R., Rohner-Jeanrenaud F., Jeanrenaud B. Chronic intracerebroventricular neuropeptide Y administration to normal rats mimics hormonal and metabolic changes of obesity. Endocrinology 1993, 133:1753-1758.
88. Turton M.D., O'Shea D., Bloom S.R. Central effects of neuropeptide Y with emphasis on its role in obesity and diabetes 1997, 15-39. Academic Press, Inc, San Diego. L. Grundemar, S.R. Bloom (Eds.).
89. Erickson J.C., Clegg K.E., Palmiter R.D. Sensitivity to leptin and susceptibility to seizures of mice lacking neuropeptide Y. Nature 1996, 381:415-418.
90. Palmiter R.D., Erickson J.C., Hollopeter G., Baraban S.C., Schwartz M.W. Life without neuropeptide Y. Recent Prog Horm Res 1998, 53:163-199.
91. Chance W.T., Balasubramaniam A., Thompson H., Mohapatra B., Ramo J., Fischer J.E. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996, 17:797-801.
92. Chance W.T., Balasubramaniam A., Fischer J.E. Neuropeptide Y and the development of cancer anorexia. Ann Surg 1995, 221:579-589.
93. Chance W.T., Balasubramaniam A., Borchers M., Fischer J.E. Refractory hypothalamic adenylate cyclase in anorectic tumor-bearing rats. Brain Res 1995, 691:180-184.
94. Chance W.T., Balasubramaniam A., Dayal R., Brown J., Fischer J.E. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994, 54:1869-1874.
95. McCarthy H.D., McKibbin P.E., Perkins A.V., Linton E.A., Williams G. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol 1993, 264:E638-E643.
96. DeBoer M.D., Zhu X.X., Levasseur P., et al. Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology 2007, 148(6):3004-3012.
97. Sonti G., Ilyin S.E., Plata-Salaman C.R. Neuropeptide Y blocks and reverses interleukin-1ß-induced anorexia in rats. Peptides 1996, 17:517-520.
98. Gayle D., Ilyin S.E., Plata-Salaman C.R. Central nervous system IL-1ß system and neuropeptide Y mRNAs during IL-1ß-induced anorexia in rats. Brain Res Bull 1997, 44:311-317.
99. Sonti G., Ilyin S.E., Plata-Salaman C.R. Anorexia induced by cytokine interactions at pathophysiological concentrations. Am J Physiol 1996, 270:R1394-R1402.
100. 1 receptor gene expression: effects of anorexigenic ciliary neurotropic factor. Regul Pept 1998, 75-76:391-395.
101. Henderson J.T., Seniuk N.A., Richardson P.M., Gauldie J., Roder J.C. Systemic administration of ciliary neurotrophic factor induces cachexia in rodents. J Clin Invest 1994, 93:2632-2638.
102. Martin D., Merkel E., Tucker K.K., et al. Cachectic effect of ciliary neurotrophic factor on innervated skeletal muscle. Am J Physiol 1996, 271:R1422-R1428.
103. Kalra S.P., Xu B., Dube M.G., Moldawer L.L., Martin D., Kalra P.S. Leptin and ciliary neurotropic factor (CNTF) inhibit fasting-induced suppression of luteinizing hormone release in rats: role of neuropeptide Y. Neurosci Lett 1998, 240:45-49.
104. Chance W.T., Balasubramaniam A., Sheriff S., Fischer J.E. Possible role of neuropeptide Y in experimental cancer anorexia. Adv Exp Med Biol 1994, 354:185-201.
105. Plata-Salaman C.R., Ilyin S.E., Gayle D. Brain cytokine mRNAs in anorectic rats bearing prostate adenocarcinoma tumor cells. Am J Physiol 1998, 275:R566-R573.
106. Gibbs J., Smith G.P. Effects of brain-gut peptides on satiety. Obesity 1992, 399-410. J. B. Lippincott Company, Philadelphia. P. Björntorp, B.N. Brodoff (Eds.).
107. 2 in the central control of feeding behavior. Nature 1996, 379:69-72.
108. Noguchi Y., Vydelingum N.A., Brennan M.F. The reversal of increased gluconeogenesis in the tumor-bearing rat by tumor removal and food intake. Surgery 1989, 106:423-431.
109. Chance W.T., van Lameren F.M., Chen M.H., Murphy R.F., Joffe S.N., Fischer J.E. Alteration in plasma levels of insulin and glucagon associated with cancer anorexia. Surg Forum 1983, 34:441-443.
110. Bartlett D.L., Charland S.L., Torosian M.H. Reversal of tumor-associated hyperglucagonemia as treatment for cancer cachexia. Surgery 1995, 118:87-97.
111. Hartl W.H., Demmelmair H., Janch K.-W., Koletzko B., Schildberg F.W. Effect of glucagon on protein synthesis in human rectal cancer in situ. Ann Surg 1998, 227:390-397.
112. Tsigos C., Papanicolaou D.A., Kyrou I., Defensor R., Mitsiadis C.S., Chrousos G.P. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab 1997, 82:4167-4170.
113. Flint A., Raben A., Holst J.J., Astrup A. Glucagon-like peptide promotes satiety and suppresses energy intake in humans. J Clin Invest 1998, 101:515-520.
114. Bloom S.R., Polak J.M. Glucagonoma syndrome. Am J Med 1987, 82(Suppl. 5B):25-36.
115. Hirosue Y., Inui A., Teranishi A., et al. Cholecystokinin octapeptide analogues suppress food intake via central CCK-A receptors in mice. Am J Physiol 1993, 265:R481-R486.
116. Morley J.E. Neuropeptide regulation of appetite and weight. Endocr Rev 1987, 8:256-287.
117. Inui A., Inoue T., Sakatani N., Oya M., Morioka H., Baba S. Proglumide has access to brain and antagonizes the central satiety effect of cholecystokinin octapeptide in the dog. Brain Res 1987, 417:355-359.
118. Inui A., Okita M., Inoue T., et al. Effect of cholecystokinin octapeptide analogues on food intake in the dog. Am J Physiol 1989, 257:R746-R751.
119. Schick R.R., Yaksh T.L., Go V.L.W. An intragastric meal releases the putative satiety factor cholecystokinin from hypothalamic neurons in cats. Brain Res 1986, 370:349-353.
120. Schick R.R., Reilly W.M., Roddy D.R., Yaksh T.L., Go V.L.W. Neuronal cholecystokinin-like immunoreactivity is postprandially released from primate hypothalamus. Brain Res 1987, 418:20-26.
121. Chance W.T., van Lammeren F.M., Chen M.H., et al. Plasma and brain cholecystokinin levels in cancer anorexia. J Surg Res 1984, 36:490-498.
122. Van Lammeren F.M., Chance W.T., Fischer J.E. Cholecystokinin-induced hypophagia is not potentiated by cancer anorexia. Peptides 1984, 5:97-101.
123. Willis G.L., Sleeman M., Smith G.C. Facilitation of cancer-associated anorexia by cholecystokinin. Regul Pept 1988, 20:119-124.
124. Daun J.M., McCarthy D.O. The role of cholecystokinin in interleukin-induced anorexia. Physiol Behav 1993, 54:237-241.
125. Bado A., Levasseur S., Attoub S., et al. The stomach is a source of leptin. Nature 1998, 394:790-793.
126. Barrachina M.D., Martinez V., Wang L., Wei J.Y., Tache Y. Synergistic interaction between leptin and cholecystokinin to reduce short-term food intake in mice. Proc Natl Acad Sci U S A 1997, 94:10455-10460.
127. Laviano A., Inui A., Marks D.L., et al. Neural control of the anorexia-cachexia syndrome. AJP Endo 2008, 295:1000-1008.
128. Bray G.A. Hereditary adiposity in mice: human lessons from the yellow and obese (ob/ob) mice. Obes Res 1996, 4:91-95.
129. Lu D., Willard D., Patel I.R., et al. Agouti protein is an antagonist of the melanocyte-stimulating hormone receptor. Nature 1994, 371:799-802.
130. Fan W., Boston B.A., Kesterson R.A., Hroby V.J., Cone R.D. Role of melanocortinergic neurons in feeding and the agouti obesity syndrome. Nature 1997, 385:165-168.
131. Huszar D., Lynch C.A., Fairchild-Huntress V., et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 1997, 88:131-141.
132. Kesterson R.A., Huszar D., Lynch C.A., Simerly R.B., Cone R.D. Induction of neuropeptide Y gene expression in the dorsal medial hypothalamic nucleus in two models of the agouti obesity syndrome. Mol Endocrinol 1997, 11:630-637.
133. Ollmann M.M., Wilson B.D., Yang Y.K., et al. Antagonism of central melanocortin receptors in vitro and in vivo by agouti-related protein. Science 1997, 278:135-138.
134. Hahn T.M., Breininger J.F., Baskin D.G., Schwartz M.W. Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurol Sci 1998, 1:271-272.
135. Adan R.A.H., Gispen W.H. Brain melanocortin receptors: from cloning to function. Peptides 1997, 18:1279-1287.
136. Catania A., Lipton J.M. α-Melanocyte stimulating hormone in the modulation of host reactions. Endocr Rev 1993, 14:564-576.
137. Uehara Y., Shimizu H., Sato N., Tanaka Y., Shimomura Y., Mori M. Carboxyl-terminal tripeptide of α-melanocyte-stimulating hormone antagonizes interleukin-1-induced anorexia. Eur J Pharmacol 1992, 220:119-122.
138. Turnbull A., Rivier C. Corticotropin-releasing factor (CRF) and endocrine responses to stress: CRF receptors, binding protein, and related peptides. Proc Soc Exp Biol Med 1997, 215:1-10.
139. Heinrichs S.C., Menzaghi F., Koob G.F. Neuropeptide Y-induced feeding and its control. Vitam Horm 1998, 54:51-66.
140. Vaughan J., Donaldson C., Bittencount J., et al. Characterization of urocortin, a novel mammalian neuropeptide related to fish urotensin and to CRF. Nature 1995, 378:287-292.
141. 2 receptors in corticotropin-releasing factor- and urocortin-induced anorexia. Neuroreport 1998, 9:1601-1606.
142. Hellerstein M.K., Meydani S.N., Meydani M., Wu K., Dinarello C.A. Interleukin-induced anorexia in the rat. J Clin Invest 1989, 84:228-235.
143. Uehara A., Sekiya C., Takasugi Y., Namiki M., Arimura A. Anorexia induced by interleukin: involvement of corticotropin-releasing factor. Am J Physiol 1989, 257:R613-R617.
144. Martinez V., Rivier J., Wang L., Tache Y. Central injection of a new corticotropin-releasing factor (CRF) antagonist, astressin, blocks CRF- and stress-related alterations of gastric and colonic motor function. J Pharmacol Exp Ther 1997, 280:754-760.
145. 2 receptors. Am J Physiol 1998, 274:G965-G970.
146. Asakawa A., Inui A., Ueno N., Makino S., Fujino M.A., Kasuga M. Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice. Gastroenterology 1999, 116:1287-1292.
147. Süto G., Kiraly A., Tache Y. Interleukin-1ß inhibits gastric emptying in rats: mediation through prostaglandin and corticotropin-releasing factor. Gastroenterology 1994, 106:1568-1575.
148. Kalra S.P., Sahu A., Dube M.G., Bonavera J.J., Kalra P.S. Neuropeptide Y and its neural connections in the etiology of obesity and associated neuroendocrine and behavioral disorders. Molecular and Genetic Aspects of Obesity 1996, 219-232. Louisiana State University Press, Baton Rouge. G.A. Bray, D.H. Ryan (Eds.).
149. Leibowitz S.F. Brain peptides and obesity: pharmacologic treatment. Obes Res 1995, 3(Suppl. 4):573S-589S.
150. Akabayashi A., Koenig J.I., Watanabe Y., Alexander J.T., Leibowitz S.F. Galanin-containing neurons in the paraventricular nucleus: a neurochemical marker for fat ingestion and body weight gain. Proc Natl Acad Sci U S A 1994, 91:10375-10379.
151. Leibowitz S.F., Akabayashi A., Wang J. Obesity on a high-fat diet: role of hypothalamic galanin in neurons of the anterior paraventricular nucleus projecting to the median eminence. J Neurosci 1998, 18:2709-2719.
152. Levine A.S., Billington C.J. Opioids. Are they regulators of feeding?. Ann N Y Acad Sci 1989, 575:209-220.
153. Pomonis J.D., Levine A.S., Billington C.J. Interaction of the hypothalamic paraventricular nucleus and central nucleus of the amygdala in naloxone blockade of neuropeptide Y-induced feeding revealed by c-fos expression. J Neurosci 1997, 17:5175-5182.
154. Kalra P.S., Fuentes M., Sahu A., Kalra S.P. Endogenous opioid peptides mediate the interleukin-1-induced inhibition of the release of luteinizing hormone (LH)-releasing hormone and LH. Endocrinology 1990, 127:2381-2386.
155. Steele T.D., Bryant H.U., Malven P.V., Yim G.K. Nocturnal depletion of hypothalamic dynorphin in anorexic Walker-256 tumor-bearing rats. Pharmacol Biochem Behav 1988, 29:541-545.
156. Morley J.E. Anorexia in older persons: epidemiology and optimal treatment. Drugs Aging 1996, 8:134-155.
157. Gagnon B., Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998, 55:675-688.
158. Rossi M., Choi S.J., O'Shea D., Miyoshi T., Ghatei M.A., Bloom S.R. Melanin-concentrating hormone acutely stimulates feeding, but chronic administration has no effect on body weight. Endocrinology 1997, 138:351-355.
159. Saito Y., Nuthacker H.P., Wang B., Lin S.H.S., Leslie F., Civelli O. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 1999, 400:265-269.
160. Shimada M., Tritos N.A., Lowell B.B., Flier J.S., Maratos-Flier E. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998, 396:670-674.
161. De Lecea L., Kilduff T.S., Peyron C., et al. The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci U S A 1998, 95:322-327.
162. Broberger C., De Lecea L., Sutcliffe J.G., Hökfelt T. Hypocretin/orexin- and melanin-concentrating hormone-expressing cells form distinct populations in the rodent lateral hypothalamus: relationship to the neuropeptide Y and agouti gene-related protein systems. J Comp Neurol 1998, 402:460-474.
163. Elias C.F., Saper C.B., Maratos-Flier E., Tritos N.A., Lee C., Kelly J. etal. Chemically defined projections linking the mediobasal hypothalamus and the lateral hypothalamic area. J Comp Neurol 1998, 402:442-459.
164. Plata-Salaman C.R. Cytokines and feeding. News Physiol Sci 1998, 13:298-304.
165. Kristensen P., Judge M.E., Thim L., et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998, 393:72-76.
166. Lambert P.D., Conceyro P.R., Mcgirr K.M., Dall Vechia S.E., Smith Y., Kuhar M.J. CART peptides in the central control of feeding and interactions with neuropeptide Y. Synapse 1998, 29:293-298.
167. Chance W.T., Muggia-Sullan M., Chen M.H., Murphy R.F., Fischer J.E. Reversal of tumor-induced biochemical abnormalities by insulin treatment in rats. J Natl Cancer Inst 1986, 77:497-503.
168. Morley J.F., Morrison S.D., Gorschboth C.M., Norton J.A. Body composition changes in rats with experimental cancer cachexia: improvement with exogenous insulin. Cancer Res 1988, 48:2784-2787.
169. Bartlett D.L., Pharm D.S.C., Torosian M.H. Growth hormone, insulin, and somatostatin therapy of cancer cachexia. Cancer 1994, 73:1499-1504.
170. Minn H., Nuutila P., Lindholm P., et al. In vivo effects of insulin on tumor and skeletal muscle glucose metabolism in patients with lymphoma. Cancer 1994, 73:1490-1498.
171. 31P magnetic resonance spectroscopy study. Cancer Res 1994, 54:6383-6386.
172. McCarthy H.D., Crowder R.E., Dryden S., Williams G. Megestrol acetate stimulates food and water intake in the rat: effects on regional hypothalamic neuropeptide Y concentrations. Eur J Pharmacol 1994, 265:99-102.
173. Campfield L.A., Smith F.J., Burn P. Strategies and potential molecular targets for obesity treatment. Science 1998, 280:1383-1387.
174. Taylor D.D., Gercel-Taylor C., Jenis L.J., Devereux D.F. Identification of a human tumor-derived lipolysis-promoting factor. Cancer Res 1992, 52:829-834.
175. Beck S.A., Mulligan H.D., Tisdale M.J. Lipolytic factors associated with murine and human cancer cachexia. J Natl Cancer Inst 1990, 82:1922-1926.
176. Todorov P.T., McDevitt T.M., Cariuk P., Coles B., Deacon M., Tisdale M.J. Induction of muscle protein degradation and weight loss by a tumor product. Cancer Res 1996, 56:1256-1261.
177. Todorov P.T., Cariuk P., McDevitt T.M., Coles B., Fearon K., Tisdale M.J. Characterization of a cancer cachectic factor. Nature 1996, 379:739-742.
178. Laviano A., Meguid M.M., Yang Z.J., Gleason J.R., Cangiano C., Rossi-Fanelli F. Cracking the riddle of cancer anorexia. Nutrition 1996, 12:706-710.
179. Muscaritoli M., Meguid M.M., Beverly J.L., Yang Z.J., Cangiano C., Rossi-Fanelli F. Mechanism of early tumor anorexia. J Surg Res 1996, 60:389-398.